U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.09
    -0.53 (-1.22%)

    Market Cap: $2.13B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(15/37)
    Avg Surprise
    -3.63%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.09
    Range$-0.07 - $0.19
    7 analysts
    EPS Revisions
    5
    0
    7d
    5
    0
    30d
    EPS Estimate Drift
    90d ago$-0.10-214.2%
    60d ago$-0.11-223.1%
    30d ago$-0.05-153.4%
    7d ago$0.09+0.0%
    Current$0.09
    Revenue Consensus
    $91M
    Range$84M - $96M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.41
    Range$-0.17 - $0.86
    7 analysts
    Revenue Consensus
    $123M
    Range$103M - $137M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.41---
    Sep 26EST
    		-$0.09---
    Jun 26
    Reported Aug 5
    		$-0.28$-0.38+26.32%Beat+73.3%
    Mar 26
    Reported May 6
    		$-0.47$-0.48+2.08%Beat+48.9%
    Dec 25
    Reported Mar 2
    		$-0.53$-0.48-9.94%Miss+33.8%
    Sep 25
    Reported Nov 6
    		$-0.69$-0.68-1.47%Miss-25.5%
    Jun 25
    Reported Aug 7
    		$-1.05$-0.82-28.05%Miss-15.4%
    Mar 25
    Reported May 12
    		$-0.92$-0.79-16.46%Miss+5.2%
    Dec 24
    Reported Mar 10
    		$-0.80$-0.72-11.11%Miss-11.1%
    Sep 24
    Reported Nov 6
    		$-0.55$-0.82+32.93%Beat+19.1%
    Jun 24
    Reported Aug 13
    		$-0.91$-0.83-9.64%Miss+11.7%
    Mar 24
    Reported May 13
    		$-0.97$-0.87-11.49%Miss+25.4%
    Dec 23
    Reported Mar 14
    		$-0.72$-0.68-5.88%Miss+41.0%
    Sep 23
    Reported Nov 14
    		$-0.68$-0.87+21.84%Beat+39.8%
    Jun 23
    Reported Aug 10
    		$-1.03$-1.14+9.65%Beat+12.7%
    Mar 23
    Reported May 11
    		$-1.30$-1.24-4.84%Miss-4.0%
    Dec 22
    Reported Mar 16
    		$-1.22$-1.07-14.02%Miss+3.9%
    Sep 22
    Reported Nov 10
    		$-1.13$-1.14+0.88%Beat+16.3%
    Jun 22
    Reported Aug 11
    		$-1.18$-1.33+11.28%Beat-0.9%
    Mar 22
    Reported May 10
    		$-1.25$-1.25+0.00%Beat-6.8%
    Dec 21
    Reported Mar 21
    		$-1.27$-1.17-8.55%Miss+8.0%
    Sep 21
    Reported Nov 15
    		$-1.35$-1.33-1.50%Miss-3.1%
    Jun 21
    Reported Aug 4
    		$-1.17$-1.09-7.34%Miss+18.8%
    Mar 21
    Reported May 13
    		$-1.17$-1.25+6.40%Beat+34.6%
    Dec 20
    Reported Mar 18
    		$-1.38$-1.37-0.73%Miss+25.8%
    Sep 20
    Reported Nov 9
    		$-1.31$-1.47+10.88%Beat-23.6%
    Jun 20
    Reported Aug 10
    		$-1.44$-1.52+5.26%Beat-33.3%
    Mar 20
    Reported May 7
    		$-1.79$-1.62-10.49%Miss-61.3%
    Dec 19
    Reported Mar 2
    		$-1.86$-1.70-9.41%Miss-27.4%
    Sep 19
    Reported Nov 12
    		$-1.06$-1.28+17.19%Beat+17.2%
    Jun 19
    Reported Aug 9
    		$-1.08$-1.20+10.00%Beat+5.3%
    Mar 19
    Reported May 9
    		$-1.11$-1.26+11.90%Beat-26.1%
    Dec 18
    Reported Feb 28
    		$-1.46$-1.24-17.74%Miss-97.3%
    Sep 18
    Reported Nov 12
    		$-1.28$-1.11-15.32%Miss-6300.0%
    Jun 18
    Reported Aug 14
    		$-1.14$-0.93-22.58%Miss-67.6%
    Mar 18
    Reported May 15
    		$-0.88$-0.72-22.22%Miss+20.7%
    Dec 17
    Reported Mar 15
    		$-0.74$-0.64-15.63%Miss-
    Sep 17
    Reported Nov 14
    		$-0.02N/A-118.18%Miss-
    Jun 17
    Reported Aug 14
    		$-0.68N/A+61.58%Beat-
    Mar 17
    Reported May 5
    		$-1.11N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-21.87EV/EBITDA-2.63x
    Price/FCF-13.64xFCF Yield-7.33%
    Profitability
    Profit Margin-51.70%Operating Margin0.15%
    ROE-1481.00%ROIC-150.11%
    Financial Health
    Debt/Equity-1.43xInterest Coverage-5.24x
    Current Ratio3.80xQuick Ratio3.41x
    Trading Statistics
    Beta1.57Avg Volume1.01M
    52-Week High$50.8152-Week Low$15.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$46.35
    SMA 20$46.52
    SMA 50$41.91
    SMA 200$27.87
    EMA 10$45.50
    EMA 20$45.29
    EMA 50$41.62
    EMA 200$30.06

    MACD

    Line: 0.92Signal: 1.78Hist: -0.87

    ADX

    ADX: 27.7+DI: 19.1-DI: 25.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$50.06

    Bollinger Bands

    Upper Band$51.23
    Lower Band$41.81
    %B Position2025%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    44.4

    Momentum Oscillators

    Stoch %K6.1
    Stoch %D8.2
    Williams %R-88.9
    ROC (10d)-12.3%
    Momentum-6.05
    CCI (20d)-132.3
    MFI (14d)51.8

    Volatility Measures

    ATR (14d)$2.10(4.9%)
    StdDev (20d)2.35
    Hist Vol71.8%(High)

    Volume Flow

    VWAP$43.36
    OBV81.4M
    AD Line43.2M
    CMF (20d)0.118

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.7x
    VWMA (20d)$47.02

    Pivot Points

    R3$47.12
    R2$46.33
    R1$44.97
    Pivot Point$44.18
    S1$42.83
    S2$42.04
    S3$40.68

    Advanced Oscillators

    TSI12.40
    Ultimate Osc42.6
    KST146.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$72.46M$50.96M$37.84M$27.48M$24.21M$20.25M$24.57M$25.20M$21.85M$18.78M$23.53M$20.85M
    Cost of Revenue$6.57M$4.14M$3.29M$3.28M$3.55M$2.33M$2.47M$2.45M$2.23M$1.73M$2.29M$2.37M
    Gross Profit$65.88M$46.82M$34.55M$24.20M$20.66M$17.92M$22.09M$22.75M$19.62M$17.05M$21.24M$18.48M
    Operating Expenses$65.77M$67.08M$53.66M$51.59M$62.11M$54.84M$49.75M$40.30M$45.46M$42.79M$35.85M$31.98M
    R&D$17.34M$15.60M$14.31M$14.01M$18.91M$19.87M$14.89M$11.36M$15.40M$15.49M$11.30M$10.23M
    SG&A$48.44M$51.49M$39.35M$37.58M$43.20M$34.97M$34.86M$28.94M$30.06M$27.30M$24.55M$21.75M
    Operating Income$111,000$-20,263,000$-19,115,000$-27,386,000$-41,448,000$-36,914,000$-27,658,000$-17,545,000$-25,839,000$-25,740,000$-14,609,000$-13,500,000
    Interest Income$599,000$608,000$903,000$979,000$1.30M$2.11M$2.75M$2.60M$1.71M$1.61M$1.54M$906,000
    Interest Expense$4.89M$4.18M$3.77M$3.37M$4.13M$4.07M$3.89M$2.72M$3.46M$2.45M$3.59M$3.81M
    Income Before Tax$-8,722,000$-28,346,000$-26,639,000$-34,401,000$-48,925,000$-43,451,000$-34,863,000$-23,582,000$-33,365,000$-32,232,000$-22,162,000$-21,888,000
    Income Tax Expense$5.63M$-4,772,000$-275,000$-1,054,000$1.01M$392,000$2.65M$91,000$38,000$54,000$3.85M$-9,000
    Net Income$-14,351,000$-23,574,000$-26,364,000$-33,347,000$-49,940,000$-43,843,000$-37,512,000$-23,673,000$-33,403,000$-32,286,000$-26,016,000$-21,879,000
    EBITDA$-4,838,000$-22,117,000$-23,067,000$-31,925,000$-45,962,000$-41,400,000$-34,726,000$-24,860,000$-31,424,000$-32,193,000$-20,972,000$-18,300,000
    EBIT$-4,434,000$-24,769,000$-23,770,000$-32,007,000$-46,092,000$-41,497,000$-33,721,000$-23,460,000$-31,612,000$-31,400,000$-20,114,000$-18,979,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about URGN

    Government Contracts

    Gov Obligations (TTM)
    $118064
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24626N0375Department of Veterans AffairsDepartment of Veterans Affairs$32844Dec 9, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock

    Mark Schoenberg, the Chief Medical Officer of UroGen Pharma, has recently sold shares in the company. This trade alert indicates a transaction involving a key insider at UroGen Pharma.

    Sahm•8/29/26•
    Somewhat-Bearish

    UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing

    UroGen Pharma (URGN) recently submitted a New Drug Application to the FDA for UGN-103, following strong share price performance. While a narrative valuation suggests the stock is overvalued at $46.86 compared to a fair value of $36.11, another view using the P/S ratio indicates it's more balanced, being below the US Biotechs average. The article advises investors to review the full picture, considering both potential rewards and warning signs.

    Sahm•8/24/26•
    Neutral

    UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing

    UroGen Pharma (URGN) recently submitted a New Drug Application to the FDA for UGN-103, backed by strong Phase 3 trial data, which has led to significant share price appreciation. Despite this momentum and a positive outlook for their minimally invasive therapies, Simply Wall St's analysis suggests the stock might be overvalued at its current price of $46.86 compared to a fair value of $36.11, though other metrics like P/S ratio present a more balanced picture. The company's future performance hinges on successful product uptake and avoiding trial setbacks, given its reliance on a narrow product set and current operating losses.

    Simply Wall Street•8/23/26•
    Neutral

    UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN)

    UroGen Pharma has submitted a New Drug Application (NDA) to the FDA for UGN-103, a mitomycin solution for recurrent low-grade non-muscle invasive bladder cancer, supported by positive Phase 3 data. This filing is a key catalyst for the company, aiming to expand its RTGel-based bladder cancer franchise beyond ZUSDURI and address prior reimbursement issues. While analysts have varying projections for UroGen's future revenue and earnings, the success of UGN-103 is crucial for its investment narrative, given ongoing losses and a limited cash runway.

    Sahm•8/22/26•
    Somewhat-Bullish

    H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75

    H.C. Wainwright has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and maintained its target price at $75. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.

    Moomoo•8/21/26•
    Bullish

    Frequently Asked Questions About URGN

    Does URGN pay dividends?
    UroGen Pharma Ltd (URGN) does not currently pay a regular dividend.
    What is URGN's market cap?
    UroGen Pharma Ltd (URGN) has a market capitalization of $2.13B with a current stock price of $43.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In